All categories: Actigraphy | Affect and Personality | ApoE and TOMM40 | Blood Measures | Brain Proteins | Clinical Diagnosis | Cognition | Cultural Experiences | Decision Making and Behavioral Economics | Demographics | Depression | Digital Pen Device | Disabilities | Female Reproductive History | Frailty | Lifestyle | Medical Conditions | Medicare Claims | Medications | Metabolism | Metabolomics | Motor and Gait | Neck, Low Back and Joint Pain | Neuroimaging | Nutrition | Olfaction | Pathology | Pulmonary Function | Sleep and Circadian Rhythms | SES and Cognitive Resources | Vision | Well-being
Currently filtering using: All categories and variables
The post-mortem neuropathologic evaluation includes a uniform structured assessment of AD pathology, cerebral infarcts, Lewy body disease, and other pathologies common in aging and dementia. The procedures follow those recommended by the National Alzheimer's Disease Coordinating Center (NACC). Pathologic diagnoses of AD use NIA-Reagan and modified CERAD criteria, and the staging of neurofibrillary pathology uses Braak Staging.
Pathologic indices and diagnoses of Alzheimer's disease
A score | Amyloid beta plaque score based on Thal plaque phase (4 levels) |
---|---|
Braak stage | Semiquantitative measure of neurofibrillary tangles |
B score | NFT stage (4 levels), derived from Braak Stage |
CERAD score | Semiquantitative measure of neuritic plaques |
C score | Neuritic plaque score (4 levels), derived from CERAD |
Global AD pathology burden | Global burden of AD pathology based on 5 regions |
AD neuropathologic change (4 levels) | AD neuropathologic change based on NIA-AA criteria - 4 levels |
AD neuropathologic change (2 levels) | AD neuropathologic change based on NIA-AA criteria - 2 levels |
NIA-Reagan diagnosis of AD - OLD | NIA-Reagan Diagnosis of Alzheimer's disease - 4 levels (none to high likelihood) |
NIA-Reagan diagnosis of AD (dichotomous) - OLD | Presence of AD based on NIA-Reagan diagnosis criteria - dichotomous |
Immunohistochemical Beta-amyloid
Diffuse plaque burden | Diffuse plaque summary based on 5 regions |
---|---|
Neuritic plaque burden | Neuritic plaque summary based on 5 regions |
Amyloid density (8 regions) | Amyloid density after square root transformation |
Amyloid - OLD | Overall amyloid level - Mean of 8 brain regions |
Semiquantitative and quantitative measures of neurofibrillary tangles (NFT)
Neurofibrillary tangles (NFT) | Semi-quantitative summary measure from 5 brain regions |
---|---|
Tangle density (8 regions) | Tangle density after square root transformation |
PHF Tau Tangle Density - OLD | Quantitative summary measure from 8 brain regions |
Nigral, limbic, and neocortical Lewy bodies as identified on sections stained with alpha-synuclein
Lewy Body disease | Pathologic diagnosis of Lewy body diseases - 4 stages |
---|---|
Lewy bodies (7 regions) | Presence of Lewy bodies in 7 regions (includes amygdala) |
Presence (yes vs no) of vascular infarctions
Presence of one or more gross chronic infarcts | Cerebral Infarctions - Binary - Gross-Chronic-Any Location |
---|---|
Presence of one or more chronic microinfarcts | Cerebral Infarctions - Binary - Micro-Chronic-Any Location |
Presence of one or more chronic infarcts | Cerebral Infarctions - Binary - Chronic-Any Size/Location |
Measures of vascular disease pathology
Cerebral atherosclerosis | Cerebral Atherosclerosis Rating - 4 levels (None - severe) |
---|---|
Cerebral amyloid angiopathy | Cerebral amyloid angiopathy - 4 stages |
Arteriolosclerosis | Arteriolosclerosis - 4 stages |
Neuronal cell loss and gliosis in the hippocampus
Presence of hippocampal sclerosis | Presence of hippocampal sclerosis in mid-hippocampus |
---|
TDP-43: Hyper-phosphorylated, ubiquitinated and cleaved transactive response (TAR) DNA-binding protein 43
TDP-43 stage | TDP-43 pathology - 4 stages (8 regions) |
---|
General measures collected during autopsy such as time from death to autopsy procedure
Post-mortem interval | Time interval in hours from time of death to autopsy |
---|